NCT06062563

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

An Exploratory Study to Evaluate the Efficacy of Anlotinib Hydrochloride Combined With Penpulimab in the Treatment of Radioiodine Refractory Differentiated Thyroid Cancer With First-line Resistance to Angiogenesis Inhibitors

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to observe and explore the efficacy and safety of Anlotinib combined with penpulimab in the treatment of radioiodine refractory differentiated thyroid cancer with first-line resistance to angiogenesis inhibitors, and to summarize the treatment experience of population.

Conditions

• Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

Interventions

Type	Name	Description
DRUG	Anlotinib Hydrochloride Capsule and Penpulimab	Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously. Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.

Timeline

• Start date: 2023-11-11
• Primary completion: 2024-12-20
• Completion: 2025-08-20
• First posted: 2023-10-02
• Last updated: 2023-10-02

Locations

1 site across 1 country: China